Related Experiment Video
Updated: May 18, 2026
10:40
Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
[Adipose tissue renin-angiotensin system in obese]
Shintaro Yasue1, Ken Ebihara, Kazuwa Nakao
1Division of Endocrinology and Metabolism, National Cerebral and Cardiovascular Center, Kyoto University Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 28, 2012
Summary
Obesity activates the renin-angiotensin system (RAS), particularly in adipose tissue (A-RAS). Blocking RAS improves metabolic issues and reduces type 2 diabetes incidence in obese individuals.
Area of Science:
- Endocrinology
- Cardiovascular Science
- Metabolic Research
Context:
- Obesity is linked to renin-angiotensin system (RAS) activation.
- Adipose tissue contains all RAS components, forming an adipose RAS (A-RAS).
- Obesity-related metabolic dysfunction is influenced by A-RAS.
Purpose:
- To investigate the role of A-RAS in obesity and its associated metabolic derangements.
- To highlight the contribution of adipose tissue-derived angiotensinogen (AGT) in obesity-induced hypertension.
- To underscore the therapeutic potential of RAS blockade in obese patients.
Summary:
- Activation of the RAS is prevalent in obesity, with adipose tissue playing a key role via A-RAS.
- Angiotensin-converting enzyme (ACE) inhibitors and AT1 receptor (AT1R) blockers show efficacy in managing obesity-related metabolic issues.
- The CASE-J trial demonstrated that systemic RAS blockade significantly lowered new-onset type 2 diabetes, especially in obese hypertensive patients.
- Adipose tissue-derived AGT is elevated in obesity, contributing to hypertension and systemic RAS activation.
Impact:
- Understanding A-RAS provides insights into obesity's pathophysiology.
- Targeting A-RAS may offer novel therapeutic strategies for obesity and related metabolic disorders.
- RAS inhibition demonstrates potential in preventing type 2 diabetes in obese populations.
More Related Videos
Related Concept Videos
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:21External Anatomy of the Kidney
The kidneys are a pair of bean-shaped organs in the human body that play a critical role in maintaining overall health. They filter out waste products from the blood, regulate blood pressure, maintain electrolyte balance, and stimulate the production of red blood cells.
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
The kidneys are located in the retroperitoneal space on either side of the vertebral column, protected posteriorly by the 11th and 12th ribs. The right kidney sits slightly lower than the left owing to the presence of the liver...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...